Figure Legend 1.
Kaplan-Meier Plot of Survival of patients with ATL (3 chronic, 15 acute and 11 lymphomatous) who were treated with alemtuzumab (CAMPATH-1, anti-CD52). The median survival was 5.9 months.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.